Systemic Combination Treatment for Psoriasis: a Review

Total Page:16

File Type:pdf, Size:1020Kb

Systemic Combination Treatment for Psoriasis: a Review Acta Derm Venereol 2010; 90: 341–349 REVIEW ARTICLE Systemic Combination Treatment for Psoriasis: A Review Peter JENSEN, Lone SKOV and Claus ZACHARIAE Department of Dermato-Allergology, Copenhagen University Hospital Gentofte, Denmark Psoriasis is a chronic inflammatory skin disease, systemic anti-psoriatic combination regimens, to pro- which affects approximately 2.6% of the population in vide a readily available summary of studies, in which Northern Europe and Scandinavia. To achieve disease systemic treatments were combined. control, combinations of systemic treatments are so- metimes needed for variable time periods. However, no evidence-based guidelines exist for the use of systemic MateRIALS AND METHODS combination therapy. Therefore, the aim was to review We searched PubMed up to 31 October 2009 to identify all the current literature on systemic anti-psoriatic combi- retrospective and prospective studies, including case reports nation regimens. We searched PubMed, and identified published in English in which patients with psoriasis received systemic combination treatment. The search string consisted 98 papers describing 116 studies (23 randomized) that of the following free-text terms: “psoriasis”, “combined”, reported on the effect of various systemic combination “combination”, “concurrent”, and “concomitant”. The Cochrane treatments. The most thoroughly investigated combina- Controlled Trials Register was searched using the free-text tion was retinoid and phototherapy. Further controlled term “psoriasis” and no related Cochrane Systematic Review research is needed to define the safest and most effective exists. In addition, a search using the Medical Subject Heading “psoriasis” revealed no relevant studies. Review articles and combination regimens. Key words: psoriasis; systemic articles cited in original papers allowed us to identify addi- treatment; combination treatment. tional studies. Articles without information on the efficacy of treatment and studies reporting on the effect of sequential and (Accepted April 15, 2010.) rotational therapy, were excluded. No studies were excluded because of inadequate study design. Studies reporting on the Acta Derm Venereol 2010; 90: 341–349. effect on psoriatic arthritis as a primary endpoint were included if information about the effect on the cutaneous manifestations Peter Jensen, Department of Dermato-Allergology, Co- was provided. Combinations involving phototherapy (psoralen penhagen University Hospital Gentofte, Niels Andersens plus ultraviolet A (PUVA), narrowband UVB (NB-UVB) and Vej 65, DK-2900 Hellerup, Denmark. E-mail: peterj01@ broadband UVB (UVB)) were also included. This search re- geh.regionh.dk vealed 98 papers describing 116 retro- and prospective studies, of which 23 were randomized. The studies were sorted into five main groups as follows: (1) methotrexate (MTX) combinations, (2) retinoid combinations, Psoriasis is a chronic inflammatory skin disease with an (3) cyclosporine combinations, (4) biological combinations, estimated global prevalence ranging from 0.5% to 4.6% and (5) other systemic combinations. Within each of these five (1), and it affects approximately 2.6% of the population main groups, studies were subdivided according to which medi- in Northern Europe and Scandinavia (2). cation the “main” agent was combined with (Fig. 1). In these Psoriasis vulgaris, the most common form, accounts subgroups, study design, number of patients, treatment regimen and efficacy is shown either in Table I (randomized studies) for more than 80% of psoriasis cases (1). Most patients or in supplementary Table SII (available from http://adv.medi- are mildly affected and can be treated adequately caljournals.se/article/abstract/10.2340.00015555-0905/Tab2) with topical medication, but 10–20% of patients have (non-randomized studies). In many cases no clearly defined moderate-to-severe disease and require phototherapy or objectively determined inclusion criteria were stated, but or systemic treatment. Frequently, however, this does we assume that the patients had moderate-to-severe psoriasis since combination therapy was initiated. Furthermore, objec- not result in adequate disease clearance, and there- tive assessment, such as Psoriasis Area Severity Index (PASI) fore systemic treatments are sometimes combined score, was frequently missing and instead we listed investigator for variable time periods to achieve an additive or comments on the effect of treatment. Some studies report on synergistic effect. Dosages of the individual agents several different combinations and may therefore appear in may then be reduced to minimize side effects. Also, more than one group. in patients with moderate-to-severe psoriasis, combi- nation therapy is often administered for shorter time RESULTS periods while mono therapy is changed from one drug to another. Combination therapies with methotrexate No evidence-based guidelines exist for the use of systemic combination treatment. The purpose of this We identified 20 studies in which MTX was given in study was therefore to review the current literature on combination with another systemic drug. Six studies © 2010 The Authors. doi: 10.2340/00015555-0905 Acta Derm Venereol 90 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 342 P. Jensen et al. 116 studies (23 randomized) MTX and: Retinoid and: Cyclosporine and: Biologics and: Other systemic Cyclosporine (6) Phototherapy (25) PUVA (2) MTX (15) combinations (7) Fig. 1. Number of studies in each Phototherapy (6) Other (4) Retinoid (5) Phototherapy (10) of the five main groups. MTX: Other (2) Retinoid (10) Retinoids (7) methotrexate; PUVA: psoralen plus Betamethasone (1) Cyclosporine (6) Other (10) ultraviolet A. (124 patients) reported on the effect of combining MTX Combination therapies with retinoids with cyclosporine (3–8). The study by Fraser et al. (3) (Table I) randomized patients with psoriatic arthritis Twenty-nine studies included retinoids in combination and psoriasis to receive either MTX and placebo or with another systemic treatment. Twenty-six of these MTX and cyclosporine. The study showed a statistically studies (1205 patients) examined the effect of combi- significant difference between groups on PASI and ning retinoids with phototherapy (24–49). In the seven psoriatic arthritis in favour of combination therapy. In randomized studies (Table I) patients were generally the five remaining uncontrolled studies (Table SII) a allocated to receive either PUVA and placebo or reti- beneficial effect of combining MTX with cyclosporine noid and PUVA. These controlled data show that the was reported, apart from one case series of four patients combination of PUVA and retinoid usually achieved published by Korstanje et al. (7). In this report three disease clearance faster than placebo and PUVA or reti- out of four patients experienced worsening of their noid monotherapy, and that fewer UVA exposures were psoriasis, which occurred following a dose reduction needed in the groups that received UVA combined with of cyclosporine due to side effects. In addition, several a retinoid. There seemed to be no difference between studies have demonstrated effect and safety of combined etretinate and acitretin regarding efficacy. Ruzicka et al. treatment with MTX and cyclosporine in patients with (30) and Lowe et al. (31) (Table I) randomly allocated rheumatoid arthritis (9, 10). patients to receive either acitretin and UVB or placebo Six studies examined the effect of combining MTX and UVB, and also showed that combination therapy with phototherapy (125 patients) (11–16). A randomi- with UVB and retinoids had a significantly increased zed study by Asawanonda & Nateetongrungsak (11) effect on PASI. With regards to type of phototherapy, (Table I) showed a significantly better effect of com- Özdemir et al. (24) randomized patients to receive bined treatment with MTX and NB-UVB compared either acitretin and PUVA or acitretin and NB-UVB and with NB-UVB monotherapy. Similarly, Shehzad et al. concluded that both regimens were equally effective. (12) (Table I) demonstrated that patients randomized The large number of papers reporting on the retinoid to MTX and concomitant PUVA therapy achieved and phototherapy combination reflects the widespread clearance earlier than patients treated with either use of this combination. This is in accordance with the PUVA or MTX mono therapy. All studies, including general conception that this combination is a safe and four non-randomized reports (Table SII), support that effective treatment for moderate-to-severe psoriasis. an additive effect is achieved when combining MTX For the 18 non-randomized studies, see Table SII. and phototherapy, but the long-term risk of skin can- Retinoids were combined in various uncommon ways cer may be increased and this should be taken into in three studies (50–52). The study by Ezquerra et al. consideration. (50) (Table I) randomized patients to receive either MTX was combined with either acitretin or etretinate acitretin monotherapy or acitretin and per oral calcitriol in seven studies (25 patients) (16–22) (Table SII). No and demonstrated a significantly greater PASI reduction randomized data exist, and the available retrospective in the combination group. Mittal et al. (51) (Table I) data and case reports all show that MTX combined with randomly assigned patients to either acitretin and pla- retinoids led to disease clearance. It is noteworthy that cebo or acitretin and pioglitazone (anti-diabetic), and only 25
Recommended publications
  • Advances in Immunosuppression for Renal Transplantation Antoine Durrbach, Helene Francois, Severine Beaudreuil, Antoine Jacquet and Bernard Charpentier
    REVIEWS Advances in immunosuppression for renal transplantation Antoine Durrbach, Helene Francois, Severine Beaudreuil, Antoine Jacquet and Bernard Charpentier Abstract | The development of immunosuppressants with minimal adverse and nephrotoxic effects is important to improve outcomes, such as acute and chronic antibody-mediated rejection, after organ transplantation. In addition, the application of expanded criteria for donors and transplantation in immunized patients necessitates the development of new therapies. Drug development over the past 10 years has generally been disappointing, but several new promising compounds have been or are being developed to prevent acute and chronic transplant rejection. In this Review, we report on several compounds that have been developed to remove allogenic T cells and/or to inhibit T-cell activation. We also discuss compounds that interfere with antibody-mediated rejection. Durrbach, A. et al. Nat. Rev. Nephrol. 6, 160–167 (2010); published online 2 February 2010; doi:10.1038/nrneph.2009.233 Introduction Renal transplantation has specific features that make or as a result of previous transplantation, has increased it different from transplantation procedures for other over the past decade. In addition, ABO­incompatible organs. For example, outcomes can be affected by grafts are becoming more frequently used. Together, these common states, such as donor and/or recipient age, high factors have led to a rise in the number of ‘immuno logically blood pressure, diabetes mellitus, metabolic disturbances at­risk’ kidney transplantations. Few immunosuppressants (such as high LDL cholesterol) and abnormalities in fluid targeted to B cells have, however, been available to control and electrolyte balance. The kidney is also very sensitive the antibody­mediated response.
    [Show full text]
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Biologic Armamentarium in Psoriasis
    Vol 9, Issue 1, 2016 ISSN - 0974-2441 Review Article BIOLOGIC ARMAMENTARIUM IN PSORIASIS GANESH PAI1*, NITHIN SASHIDHARAN2 1Medical Director, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. 2Consultant Clinical Pharmacologist, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. Email: [email protected] Received: 14 July 2015, Revised and Accepted: 24 August 2015 ABSTRACT Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional treatments, and biologic therapies potential. Keywords: Psoriasis, Biologic, Non-biologic treatment. INTRODUCTION migration, potentiation of Th1 type of response, angiogenesis, and epidermal hyperplasia [7]. Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition with prevalence ranging 1-3% in the TNF- is plays vital role in the pathogenesis of psoriasis. It acts by world [1].
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • Alefacept for Severe Alopecia Areata a Randomized, Double-Blind, Placebo-Controlled Study
    STUDY Alefacept for Severe Alopecia Areata A Randomized, Double-blind, Placebo-Controlled Study Bruce E. Strober, MD, PhD; Kavita Menon, MD; Amy McMichael, MD; Maria Hordinsky, MD; Gerald Krueger, MD; Jackie Panko, MD; Kimberly Siu, MD; Jonathan L. Lustgarten, PhD; Elizabeth K. Ross, MD; Jerry Shapiro, MD Objective: To assess the efficacy of alefacept for the treat- istration–approved T-cell biologic inhibitor for the treat- ment of severe alopecia areata (AA). ment of moderate to severe plaque psoriasis. Design: Multicenter, double-blind, randomized, placebo- Main Outcome Measure: Improved Severity of Alo- controlled clinical trial. pecia Tool (SALT) score over 24 weeks. Results: Participants receiving alefacept for 12 consecu- Setting: Academic departments of dermatology in the tive weeks demonstrated no statistically significant im- United States. provement in AA when compared with a well-matched placebo-receiving group (P =.70). Participants: Forty-five individuals with chronic and severe AA affecting 50% to 95% of the scalp hair and re- Conclusion: Alefacept is ineffective for the treatment of sistant to previous therapies. severe AA. Intervention: Alefacept, a US Food and Drug Admin- Arch Dermatol. 2009;145(11):1262-1266 LOPECIA AREATA (AA) IS A lesions of AA are transplanted into mice chronic, potentially revers- with severe combined immunodefi- ible autoimmune skin dis- ciency that lack T lymphocytes, hair ease characterized by non- growth may resume, further confirming scarring patchy hair loss the potential pathogenic role of T lym- Ainvolving any hair-bearing surface.1 Alo- phocytes.8 pecia areata often causes considerable emo- Treatment options for more severe pre- tional distress and has limited treatment sentations of AA are limited, and neither Author Affiliations: options.
    [Show full text]
  • Nurse-Led Drug Monitoring Clinic Protocol for the Use of Systemic Therapies in Dermatology for Patients
    Group arrangements: Salford Royal NHS Foundation Trust (SRFT) Pennine Acute Hospitals NHS Trust (PAT) Nurse-led drug monitoring clinic protocol for the use of systemic therapies in dermatology for patients with inflammatory dermatoses Lead Author: Dawn Lavery Dermatology Advanced Nurse Practitioner Additional author(s) N/A Division/ Department:: Dermatology, Clinical Support and Tertiary Medicine Applies to: (Please delete) Salford Royal Care Organisation Approving Committee Dermatology clinical governance committee Salford Royal Date approved: 13 February 2019 Expiry date: February 2022 Contents Contents Section Page Document summary sheet 1 Overview 2 2 Scope & Associated Documents 2 3 Background 3 4 What is new in this version? 3 5 Policy 4 Drugs monitored by nurses 4 Acitretin 7 Alitretinoin Toctino 11 Apremilast 22 Azathioprine 26 Ciclosporin 29 Dapsone 34 Fumaric Acid Esters – Fumaderm and Skilarence 36 Hydroxycarbamide 39 Hydroxychloroquine 43 Methotrexate 50 Mycophenolate moefetil 57 Nurse-led drug monitoring clinic protocol for the use of systemic therapies in dermatology for patients with inflammatory dermatoses Reference Number GSCDerm01(13) Version 3 Issue Date: 11/06/2019 Page 1 of 77 It is your responsibility to check on the intranet that this printed copy is the latest version Standards 67 6 Roles and responsibilities 67 7 Monitoring document effectiveness 67 8 Abbreviations and definitions 68 9 References 68 10 Appendices N/A 11 Document Control Information 71 12 Equality Impact Assessment (EqIA) screening tool 73 Group arrangements: Salford Royal NHS Foundation Trust (SRFT) Pennine Acute Hospitals NHS Trust (PAT) 1. Overview (What is this policy about?) The dermatology directorate specialist nurses are responsible for ensuring prescribing and monitoring for patients under their care, is in accordance with this protocol.
    [Show full text]
  • Cytokine and CAM Antagonists and Related Agents Review 01/22/2010
    Cytokine and CAM Antagonists and Related Agents Review 01/22/2010 Copyright © 2005 - 2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Email comments and suggestions to [email protected].
    [Show full text]
  • Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 May 2019 doi:10.20944/preprints201905.0358.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2019, 20, 3210; doi:10.3390/ijms20133210 1 of 39 1 Review 2 Recent topics on the mechanisms of 3 immunosuppressive therapy-related neurotoxicities 4 Wei Zhang 1, Nobuaki Egashira 1,2,* and Satohiro Masuda 1,2 5 1 Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, 6 Kyushu University, Fukuoka 812-8582, Japan 7 2 Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan 8 * Correspondence: [email protected], Tel.: 81-92-642-5920 9 Abstract: Although transplantation procedures have been developed for patients with end-stagec 10 hepatic insufficiency or other diseases, allograft rejection still threatens patient health and lifespan. 11 Over the last few decades, the emergence of immunosuppressive agents, such as calcineurin 12 inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors, have strikingly 13 increased graft survival. Unfortunately, immunosuppressive agent-related neurotoxicity is 14 commonly occurred in clinical situations, with the majority of neurotoxicity cases caused by CNIs. 15 The possible mechanisms whereby CNIs cause neurotoxicity include: increasing the permeability 16 or injury of the blood-brain barrier, alterations of mitochondrial function, and alterations in 17 electrophysiological state. Other immunosuppressants can also induce neuropsychiatric 18 complications. For example, mTOR inhibitors induce seizures; mycophenolate mofetil induces 19 depression and headache; methotrexate affects the central nervous system; mouse monoclonal 20 immunoglobulin G2 antibody against cluster of differentiation 3 also induces headache; and 21 patients using corticosteroids usually experience cognitive alteration.
    [Show full text]
  • Alefacept for Psoriasis and Psoriatic Arthritis a B Gottlieb
    iv58 Ann Rheum Dis: first published as 10.1136/ard.2005.042655 on 20 October 2005. Downloaded from REPORT Alefacept for psoriasis and psoriatic arthritis A B Gottlieb ............................................................................................................................... Ann Rheum Dis 2005;64:iv58–iv60. doi: 10.1136/ard.2005.042655 there was no evidence of tachyphylaxis during multiple Alefacept is a bioengineered fusion protein of soluble courses of treatment12 lymphocyte function antigen (LFA-3) with Fc fragments of IgG1. It is marketed in many countries for the treatment of moderate to severe psoriasis. This paper reviews the data Monitoring drug safety supporting the use of alefacept in psoriasis and psoriatic The safety profile of alefacept is encouraging, with some arthritis. patients having received up to nine courses of alefacept in phase 2 and 3 clinical trials and their extensions. There was no increase in adverse events in patients treated with alefacept compared with placebo.5 Consistent with memory effector T cell depletion as a mechanism of action was the lefacept is a bioengineered fusion protein of soluble requirement for weekly monitoring of circulating CD4+ T cell Lymphocyte Function Antigen (LFA-3)1 with Fc frag- counts during the 12 dosing weeks in phase 3 clinical trials. ments of IgG1. It is marketed in the USA, Australia, A Patients did not start taking alefacept if their CD4+ T cell Canada, Argentina, Switzerland, Kuwait, and Israel as count was ,400; dosing was withheld when the CD4+ T cell monotherapy for the treatment of moderate to severe count fell below 250. However, patients whose CD4+ T cell psoriasis vulgaris. It binds to CD2 on memory effector T cells counts fell below 250 in clinical trials did not experience an and blocks the interaction between LFA-3 on antigen increased incidence of infection.11 There was no increased presenting cells (APCs) and CD2 on the activated T cells.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Alefacept), for Injection, for Intramuscular Use  Serious Infections: AMEVIVE® May Increase the Risk of Infection and Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------WARNINGS AND PRECAUTIONS------------------------- These highlights do not include all the information needed to use Lymphopenia: Induces dose-dependent reductions in circulating CD4+ AMEVIVE® safely and effectively. See full prescribing information for and CD8+ T lymphocyte counts (5.1) AMEVIVE®. Malignancies: May increase the risk of malignancies. Do not administer to patients with a history of systemic malignancy (5.2) AMEVIVE® (alefacept), for injection, for intramuscular use Serious Infections: AMEVIVE® may increase the risk of infection and Initial U.S. Approval: 2003 reactivate latent, chronic infections. Do not administer to patients with a clinically important infection. Monitor new infections closely (5.3) ---------------------------INDICATIONS AND USAGE---------------------------- Potential for excessive immunosuppression when used with other AMEVIVE® is a CD2-directed LFA-3/Fc fusion protein indicated for the immunosuppressive agents or phototherapy (5.4) treatment of adult patients with moderate to severe chronic plaque psoriasis Hypersensitivity Reactions: Urticaria and angioedema have been ® who are candidates for systemic therapy or phototherapy (1). associated with the administration of AMEVIVE (5.6) Hepatic Injury: Post-marketing reports of liver injury. Discontinue use in -----------------------DOSAGE AND ADMINISTRATION----------------------- patients who develop clinical signs of liver injury (5.7) 15 mg given once weekly as an intramuscular injection for 12 weeks (2). AMEVIVE should not be initiated if CD4+ lymphocytes are below -------------------------------ADVERSE REACTIONS------------------------------ normal. Monitor CD4+ T lymphocyte counts every two weeks during the Most common adverse reactions (incidence ≥ 2%) are: pharyngitis, dizziness, dosing period. If CD4+ T lymphocyte counts are below 250 cells/µL, increased cough, nausea, pruritus, myalgia, chills, injection site pain, injection withhold dosing and institute weekly monitoring.
    [Show full text]